P/ 310-827-7707 | F/ 310-574-4002 | MAIL@PROSTATEONCOLOGY.COM
Indigo (Relapsed Disease) occurs when surgery, radiation, or some form of focal therapy fail to cure the disease. Men who are Low-Indigo are judged to be at very low risk for harboring any lymph node metastases. To qualify as Low-Indigo the PSA must be under 0.5 after previous surgery, less than 5.0 after previous radiation or focal therapy and the PSA doubling time must be over 8 months. In addition, the original Stage of Blue prior to initial therapy with surgery, radiation or focal therapy must be Sky, Low- or Basic-Teal. Men with High-Indigo have metastases, but only into the pelvic lymph nodes. The metastases are proven to exist by either by surgery or with scans showing unequivocal pelvic node involvement. Scans and surgical pelvic lymph node staging in men with Basic-Indigo show no overt lymph node metastases. However, in men with Basic-Indigo, various factors suggest a significant likelihood that microscopic pelvic lymph node disease is present. Such factors include higher PSA levels, a fast PSA doubling time or a Stage of Blue prior to initial treatment with surgery or radiation that was higher than Basic-Teal. The intensity of treatment selected for Low-Indigo may be relatively mild since less aggressive therapy may be curative and further options can subsequently be implemented if necessary. Aggressive combination therapy is often used for Basic- and High-Indigo for two reasons: To enhance longevity and to eliminate the need for lifelong hormonal therapy, resulting in a better quality of life.
“Like any other treatment decision we’re looking at risk-benefit ratios, we’re looking at what other options do we have?” LISTEN TO THE EPISODE For men with limited options, clinical trials …
COUNTDOWN. MARK YOUR CALENDARS. Have you subscribed the PROSTATE PROS podcast? Be one of the first to know about a new podcast release! Questions about prostate cancer you want to …
The PSMA PET Scan is changing the way doctors decide what treatments to recommend for prostate cancer. Accurate assessment of a cancer spread is essential. Until now, physicians estimated the …
Listen: https://soundcloud.com/prostate-oncology/breakthroughs-in-radiation “What makes modern radiation so special compared to the older technology is the precision targeting.” — Dr. Scholz With unwanted side effects and poor cure rates, radiation used …
Listen: https://soundcloud.com/prostate-oncology/proceeding-to-top-seed-1 “Urinary incontinence or leakage is quite rare after a seed implant, but it’s extremely common after surgery. This is another way that seed implants really shine when comparing …
How to Sequence Taxotere, Jevtana, Xtandi, and Zytiga By Mark Scholz, MD Since the advent of effective second-generation hormonal therapies such as Zytiga or Xtandi, prostate cancer experts have been …
MARINA DEL REY, Calif., May 6, 2019 /PRNewswire/ — PROSTATE PROS is a new monthly podcast hosted by prostate cancer specialist and author Mark Scholz, MD. Beginning June 03, 2019, …
BY MARK SCHOLZ, MD What Is the Best Therapy for Me? This is one of the greatest questions for men with prostate cancer. How do you arrive at a reliable …
BY MARK SCHOLZ, MD Unhealthy diets encourage prostate cancer’s growth and spread. Consider Asia, where mortality from prostate cancer is eighteen times lower than in the United States. Genetic factors …
BY MARK SCHOLZ, MD PSA testing is an essential part of prostate cancer treatment, and it is done at various stages in a patient’s journey. Initial PSA screening of healthy …